Dual Eligible (Medicare + Medicaid)? How the GLP-1 Bridge Works for You

If you're dually eligible — enrolled in both Medicare and Medicaid — you're used to a simple rule of thumb at the pharmacy counter: between Medicaid and the Part D Extra Help program (also called the Low-Income Subsidy, or LIS), your prescriptions usually cost a few dollars at most, and often nothing.

The Medicare GLP-1 Bridge, which launched July 1, 2026, breaks that rule of thumb. The Bridge lets eligible Part D beneficiaries fill covered GLP-1 medications — Wegovy (injectable and oral), the Zepbound KwikPen, and others — for a flat $50 monthly copay. Dual eligibles can absolutely participate. But the demonstration's rules say the $50 is the same for everyone: Extra Help cost-sharing does not apply, and neither does the Part D deductible or the $2,100 out-of-pocket cap.

That design has real consequences for people living on fixed, limited incomes — and it's exactly the kind of detail that's easy to discover only after a confusing bill at the pharmacy. This guide covers what duals need to know: how to qualify, why the copay works the way it does, the state Medicaid alternative, and practical options if $50 a month is genuinely out of reach.

Being on Medicaid does not disqualify you from the Bridge. The requirements are the same as for every other Part D beneficiary:

• You're enrolled in an eligible plan — a stand-alone Part D plan or a Medicare Advantage plan with drug coverage. That includes D-SNPs (Dual Eligible Special Needs Plans), the Medicare Advantage plans designed specifically for people with both Medicare and Medicaid. Plans were enrolled in the Bridge automatically; there's no separate sign-up for you to complete.
• You meet one of the three clinical eligibility doors — based on body-mass index alone or BMI plus specific conditions such as uncontrolled hypertension, heart failure, chronic kidney disease, prediabetes, or a prior heart attack or stroke. Our eligibility wizard walks you through them in about a minute.
• Your prescriber gets prior authorization approved, attesting the medication is prescribed for weight management. The step-by-step application guide covers exactly what your doctor submits.

KFF estimates that nearly four million Medicare beneficiaries met the Bridge's clinical criteria — and because obesity and its related conditions are more common at lower incomes, dual eligibles are heavily represented in that group.

Here's the part that surprises almost everyone. Under regular Part D rules, Extra Help caps what LIS beneficiaries pay for covered drugs at a few dollars per prescription. The Bridge doesn't work that way. Because it's a demonstration program that sits outside the normal Part D benefit, CMS set a single flat copay — and the program rules state that LIS cost-sharing subsidies do not apply.

In practice, that means a dual eligible who pays $1.60 for most generics and $4.90 for most brand-name drugs will pay the full $50 every month for a Bridge GLP-1 — the same as a beneficiary with no subsidy at all. Three related quirks follow from the same design:

KFF has flagged this directly as an equity concern: for low- and modest-income beneficiaries, $50 a month — $600 a year — may simply be unaffordable, even though they qualify on paper. If you see a $50 charge at the pharmacy despite having Extra Help, it is not a billing error; it's how the demonstration was built. (For how the cap interacts with the Bridge in general, see our $2,100 cap explainer.)

Dual eligibles have something other Bridge participants don't: a second insurer. And for weight-loss medications specifically, that matters more than usual.

Weight-loss drugs have historically been on Medicare Part D's list of excluded drug categories — which is exactly why the Bridge had to be created as a special demonstration. But federal Medicaid rules allow state Medicaid programs to choose to cover those excluded categories, and Medicaid coverage of Part D-excluded drugs is available even to dual eligibles, who otherwise get essentially all their drug coverage through Medicare.

The catch is that state participation is a patchwork, and it's shrinking: per KFF, about 13 state Medicaid programs covered GLP-1s for obesity as of January 2026, down from 16 the year before, with several states dropping coverage for budget reasons. Where coverage exists, a Medicaid fill may cost you far less than $50 — but it comes with its own prior authorization rules and often stricter criteria.

There's also a moving piece worth knowing about: the BALANCE Model, a separate CMS demonstration that offers participating state Medicaid programs steep supplemental rebates on GLP-1s. States are joining on a rolling basis between May 2026 and January 2027, which means some states that don't cover GLP-1s today may add coverage soon — and states that do cover them may expand access. (The Part D side of BALANCE was indefinitely delayed in April 2026, which is why the Bridge was extended through 2027 instead.)

Bottom line: check both doors. Our 50-state Medicaid coverage table is a starting point, but state policies change quarterly — always confirm with your state Medicaid office before assuming coverage either way.

If you're dually eligible and interested in a GLP-1 for weight management, here's the order that saves the most time and money: